China Resources Double-Crane PharmaceuticalLtd 将来の成長

Future 基準チェック /16

China Resources Double-Crane PharmaceuticalLtd利益と収益がそれぞれ年間16.6%と8.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13% 16.3%なると予測されています。

主要情報

16.6%

収益成長率

16.3%

EPS成長率

Pharmaceuticals 収益成長	18.8%
収益成長率	8.9%
将来の株主資本利益率	13.0%
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

Oct 21

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Sep 30

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

業績と収益の成長予測

SHSE:600062 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	12,940	2,110	N/A	2,565	2
12/31/2025	12,888	1,910	N/A	2,313	3
12/31/2024	11,903	1,734	N/A	1,892	3
9/30/2024	10,322	1,348	1,082	1,840	N/A
6/30/2024	10,308	1,395	1,207	1,801	N/A
3/31/2024	10,285	1,374	1,201	1,812	N/A
12/31/2023	10,222	1,333	1,026	1,631	N/A
9/30/2023	10,916	1,584	1,296	1,811	N/A
6/30/2023	10,558	1,428	1,028	1,514	N/A
3/31/2023	9,880	1,223	888	1,357	N/A
12/31/2022	9,625	1,180	890	1,416	N/A
9/30/2022	9,394	1,025	611	1,258	N/A
6/30/2022	9,392	1,078	720	1,337	N/A
3/31/2022	9,222	981	618	1,198	N/A
12/31/2021	9,112	936	849	1,341	N/A
9/30/2021	9,006	1,021	904	1,269	N/A
6/30/2021	8,987	1,046	964	1,328	N/A
3/31/2021	8,730	1,016	956	1,318	N/A
12/31/2020	8,504	1,005	1,012	1,360	N/A
9/30/2020	8,348	1,010	956	1,238	N/A
6/30/2020	8,663	971	1,068	1,323	N/A
3/31/2020	8,930	1,001	1,123	1,347	N/A
12/31/2019	9,381	1,055	1,198	1,440	N/A
9/30/2019	9,322	1,043	1,192	1,430	N/A
6/30/2019	9,003	1,024	1,195	1,428	N/A
3/31/2019	8,720	997	1,289	1,541	N/A
12/31/2018	8,225	969	1,240	1,469	N/A
9/30/2018	7,975	962	1,386	1,589	N/A
6/30/2018	7,434	905	N/A	1,406	N/A
3/31/2018	7,032	908	N/A	1,271	N/A
12/31/2017	6,422	843	N/A	1,187	N/A
9/30/2017	6,103	838	N/A	1,071	N/A
6/30/2017	5,725	801	N/A	1,107	N/A
3/31/2017	5,584	767	N/A	911	N/A
12/31/2016	5,495	714	N/A	771	N/A
9/30/2016	5,490	705	N/A	828	N/A
6/30/2016	5,414	684	N/A	775	N/A
3/31/2016	5,274	645	N/A	813	N/A
12/31/2015	5,138	661	N/A	701	N/A
9/30/2015	5,733	865	N/A	1,025	N/A
6/30/2015	5,562	832	N/A	1,016	N/A
3/31/2015	5,413	785	N/A	876	N/A
12/31/2014	5,153	737	N/A	929	N/A
9/30/2014	4,276	776	N/A	674	N/A
6/30/2014	5,184	845	N/A	539	N/A
3/31/2014	6,010	859	N/A	637	N/A
12/31/2013	6,835	871	N/A	546	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600062の予測収益成長率 (年間16.6% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 600062の収益 ( 16.6% ) CN市場 ( 26.1% ) よりも低い成長が予測されています。

高成長収益: 600062の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600062の収益 ( 8.9% ) CN市場 ( 13.8% ) よりも低い成長が予測されています。

高い収益成長: 600062の収益 ( 8.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600062の自己資本利益率は、3年後には低くなると予測されています ( 13 %)。

China Resources Double-Crane PharmaceuticalLtd 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Consensus EPS estimates increase by 11%

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 26% to CN¥24.32

Price target increased to CN¥19.26

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 3Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 15%

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Consensus EPS estimates increase by 11%

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘